JAMUNARANI VEERARAGHAVAN

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
AddressOne Baylor Plaza
vCardDownload vCard
    Other Positions
    TitleAssistant Professor
    InstitutionBaylor College of Medicine
    DepartmentBreast Center
    DivisionBreast Cancer Center


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, Wang T, Pascual T, Selenica P, Sanchez K, Nitta H, Kapadia M, Pavlick AC, Galvan P, Rexer B, Forero-Torres A, Nanda R, Storniolo AM, Krop IE, Goetz MP, Nangia JR, Wolff AC, Weigelt B, Reis-Filho JS, Hilsenbeck SG, Prat A, Osborne CK, Schiff R, Rimawi MF. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109. PMID: 37195235; PMCID: PMC10923553.
      Citations: 2     Fields:    Translation:Humans
    2. Fu X, Pereira R, Liu CC, De Angelis C, Shea MJ, Nanda S, Qin L, Mitchell T, Cataldo ML, Veeraraghavan J, Sethunath V, Giuliano M, Gutierrez C, Gyorffy B, Trivedi MV, Cohen O, Wagle N, Nardone A, Jeselsohn R, Rimawi MF, Osborne CK, Schiff R. High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. Cell Rep. 2023 Aug 29; 42(8):112821. PMID: 37467106.
      Citations:    Fields:    
    3. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4939. PMID: 34470810.
      Citations:    Fields:    
    4. Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff R. Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer. 2021 May 27; 7(1):63. PMID: 34045483; PMCID: PMC8159999.
      Citations: 1     
    5. Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea MJ, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XS. Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662. PMID: 33542078; PMCID: PMC8653766.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    6. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882. PMID: 33536276; PMCID: PMC8628647.
      Citations: 11     Fields:    Translation:HumansCells
    7. Liu CC, Veeraraghavan J, Tan Y, Kim JA, Wang X, Loo SK, Lee S, Hu Y, Wang XS. A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4, Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers. Clin Cancer Res. 2021 02 01; 27(3):785-798. PMID: 33172895; PMCID: PMC7934498.
      Citations: 4     Fields:    Translation:HumansCells
    8. Li L, Lin L, Veeraraghavan J, Hu Y, Wang X, Lee S, Tan Y, Schiff R, Wang XS. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Res. 2020 08 08; 22(1):84. PMID: 32771039; PMCID: PMC7414578.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    9. Schettini F, Conte B, Rognoni C, Griguolo G, Guarneri V, Conte PF, Locci M, Brase JC, Gonzalez-Farre B, Villagrasa P, De Placido S, Schiff R, Veeraraghavan J, Rimawi MF, Osborne CK, Perou CM, Carey LA, Pascual T, Chic N, Bras?-Maristany F, Galv?n P, Mart?nez O, Adamo B, Vidal M, Mu?oz M, Fern?ndez-Martinez A, Pernas S, Prat A. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2020 Mar; 84:101965. PMID: 32000054; PMCID: PMC7230134.
      Citations: 21     Fields:    Translation:Humans
    10. De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Rexer B, Forero A, Wolff AC, Veeraraghavan J, Krop I, Pavlick AC, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF, Prat A, Pascual T, Cort?s J, Par? L, Morales S, Adamo B, Bras?-Maristany F, Vidal M, Galv?n P, Bermejo B. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54. PMID: 31037288; PMCID: PMC7850037.
      Citations: 38     Fields:    Translation:Humans
    11. Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020 04; 17(4):233-250. PMID: 31836877; PMCID: PMC8023395.
      Citations: 51     Fields:    Translation:Humans
    12. Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, Reis-Filho JS, Cohen O, Wagle N, Nardone A, Jeselsohn R, Brown M, Rimawi MF, Osborne CK, Schiff R. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc Natl Acad Sci U S A. 2019 Dec 26; 116(52):26823-26834. PMID: 31826955; PMCID: PMC6936436.
      Citations: 34     Fields:    
    13. Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK, Translational Breast Cancer Research Consortium. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827. PMID: 31662331.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    14. De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745. PMID: 31653641; PMCID: PMC7002194.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    15. Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R, Simon LM. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330. PMID: 31420371; PMCID: PMC6825570.
      Citations: 19     Fields:    Translation:HumansCells
    16. Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019 06 01; 30(6):927-933. PMID: 30903140; PMCID: PMC6594453.
      Citations: 17     Fields:    Translation:Humans
    17. Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339. PMID: 30555156; PMCID: PMC6353941.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    18. Veeraraghavan J, De Angelis C, Reis-Filho JS, Prat A, Rimawi MF, Osborne CK, Schiff R, Pascual T. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast. 2017 Aug; 34 Suppl 1:S19-S26. PMID: 28687441; PMCID: PMC6050048.
      Citations: 21     Fields:    Translation:HumansCells
    19. Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134. PMID: 28487443; PMCID: PMC5762201.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    20. Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R, Wang XS. Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nat Commun. 2016 10 03; 7:12991. PMID: 27694828; PMCID: PMC5064015.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    21. Kim JA, Anurag M, Veeraraghavan J, Schiff R, Li K, Wang XS. Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint. Mol Cancer Res. 2016 10; 14(10):920-927. PMID: 27489360; PMCID: PMC5065758.
      Citations: 13     Fields:    Translation:HumansCells
    22. Veeraraghavan J, Ma J, Hu Y, Wang XS. Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. Breast Cancer Res Treat. 2016 07; 158(2):219-32. PMID: 27372070; PMCID: PMC4979600.
      Citations: 17     Fields:    Translation:Humans
    23. Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577. PMID: 25099679; PMCID: PMC4130357.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    24. Aravindan N, Thomas CR, Aravindan S, Mohan AS, Veeraraghavan J, Natarajan M. Irreversible EGFR inhibitor EKB-569 targets low-LET ?-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma. PLoS One. 2011; 6(12):e29705. PMID: 22242139; PMCID: PMC3248439.
      Citations: 9     Fields:    Translation:HumansCells
    25. Veeraraghavan J, Natarajan M, Lagisetty P, Awasthi V, Herman TS, Aravindan N. Impact of curcumin, raspberry extract, and neem leaf extract on rel protein-regulated cell death/radiosensitization in pancreatic cancer cells. Pancreas. 2011 Oct; 40(7):1107-19. PMID: 21697760.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    26. Veeraraghavan J, Natarajan M, Aravindan S, Herman TS, Aravindan N. Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB cross-signaling favors survival advantage in human neuroblastoma cells. J Biol Chem. 2011 Jun 17; 286(24):21588-600. PMID: 21527635; PMCID: PMC3122217.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    27. Aravindan N, Veeraraghavan J, Madhusoodhanan R, Herman TS, Natarajan M. Curcumin regulates low-linear energy transfer ?-radiation-induced NF?B-dependent telomerase activity in human neuroblastoma cells. Int J Radiat Oncol Biol Phys. 2011 Mar 15; 79(4):1206-15. PMID: 21236599; PMCID: PMC3071590.
      Citations: 18     Fields:    Translation:HumansCells
    28. Veeraraghavan J, Aravindan S, Natarajan M, Awasthi V, Herman TS, Aravindan N. Neem leaf extract induces radiosensitization in human neuroblastoma xenograft through modulation of apoptotic pathway. Anticancer Res. 2011 Jan; 31(1):161-70. PMID: 21273594.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    29. Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. Low-dose ?-radiation-induced oxidative stress response in mouse brain and gut: regulation by NF?B-MnSOD cross-signaling. Mutat Res. 2011 Jan 10; 718(1-2):44-55. PMID: 21056117.
      Citations: 17     Fields:    Translation:AnimalsCells
    30. Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. Curcumin-altered p53-response genes regulate radiosensitivity in p53-mutant Ewing's sarcoma cells. Anticancer Res. 2010 Oct; 30(10):4007-15. PMID: 21036715.
      Citations:    
    31. Madhusoodhanan R, Natarajan M, Veeraraghavan J, Herman TS, Jamgade A, Singh N, Aravindan N. NFkappaB signaling related molecular alterations in human neuroblastoma cells after fractionated irradiation. J Radiat Res. 2009 Jul; 50(4):311-24. PMID: 19436149.
      Citations: 12     Fields:    Translation:HumansCells
    32. Madhusoodhanan R, Natarajan M, Veeraraghavan J, Herman TS, Aravindan N. NFkappaB activity and transcriptional responses in human breast adenocarcinoma cells after single and fractionated irradiation. Cancer Biol Ther. 2009 May; 8(9):765-73. PMID: 19276662.
      Citations: 14     Fields:    Translation:HumansCells
    VEERARAGHAVAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (179)
    Explore
    _
    Co-Authors (16)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _